Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic
Part 1: - Advanced solid tumors with at least 1 prior systemic therapy
Evaluable or Measurable disease per RECIST 1.1.
Parts 2 and 3: Measurable disease per RECIST 1.1.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Adequate organ function
You may not be if
Prior treatment with a KRAS inhibitor
Active brain metastases or carcinomatous meningitis
History of other malignancy within 2 years
Significant cardiovascular disease
Disease or disorder that may pose a risk to patient's safety
Clareo Health | QTX3034 in Patients With KRAS G12D Mutation
